Information Provided By:
Fly News Breaks for March 19, 2019
NVRO
Mar 19, 2019 | 19:38 EDT
BMO Capital analyst Joanne Wuensch upgraded Nevro to Outperform and raised her price target to $67 from $46. The analyst states that she has long believed that the stock offers value, but the company's "successive downward revisions and management missteps" took her to the sidelines. With the appointment of Keith Grossman - a 20 year veteran in the medical device industry - as new CEO, along with two new board members, the analyst contends that Nevro is positioned for a turnaround, even if it required the company to suspend guidance.
News For NVRO From the Last 2 Days
There are no results for your query NVRO
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.